Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm glad someone else is being proactive! 😂
You’re not the only one, well maybe you’re the only one on twits, but there’s several others reaching out beyond IHUB and stocktwits
I’m not sure if you’re reading that right, but when I read roof’s post to yours I could clearly tell he was insinuating that you have only been to parent teacher conferences not med/science conferences. It was definitely sarcasm and nothing was disparaging towards teachers or students in that post, other than letting you participate in the conference. Jk
Yet, I'm the only one shamelessly pumping it on other message boards.
Yes and that theory is very obvious...it will be like a herd of stampeding Buffalo when the gate opens...
I like your theory on that ….
And that could very well be true, once they get approval on humans.
It makes a lot of sense.
"Probably not the most likely but not zero either" You and ASCM seem to basing your skepticism, that the FDA will punt this go round, on the number of items (63) the FDA requested further clarity on. But more so because of this one paragraph from the Jun 28th press release announcing application submission.....I won't ridicule you for that. But I do take exception to your deceptive style of posting. Some of which we have witnessed again here today. I've said this before and I'll say it again. Very odd behavior for someone who claims to be long here....your living proof rock bottom still has a basement.....
Dr. Korenko stated, “We are mindful that most of the twelve FDA reviewers have joined in the past two years and we anticipate they will have some comments after reviewing the extensive material in our filing, which we are prepared to address promptly.”
I think many eyes are on this and also all of those eyes have seen prior submittal(s) get rejected. I betting as soon as we have approval the flood gates open. 🤞
if enough people know about it ….
we should for sure surpass that.
Maybe not in the first 24 hours, but eventually soon after.
We need people to know.
in due time for sure they will.
But hopefully people find out about it sooner.
Is anyone still thinking we hit $1 after IDE approval?
TRUTHSOCIAL
I agree 100%
MY OWN DR is one of those
I saw him about 2 months ago shortly after the 59 page report on deaths and injuries from the vax was posted by the CDC, He asked if I had gotten the jab yet, I TOLD HIM NO as I have said since they came out, with that I asked if he has read the 59 page report from the CDC about subsequent deaths and injuries, his comment was "" WELL I HAVEN'T read it ALL YET!".
I looked at him and said DOC you disappoint me very much and he h said WHY, my response was YOU'VE NOT READ ONE SINGLE PAGE OF IT as it was all REDACTED and BLACK OUT so you could read nothing, you should have seen the look on his face
I like to add more shares before IDE approval, not after when PPS will be too expensive. Now just waiting for cash.
Exactly. We'll never become a meme stock 😭
Their web guy needs to update the red banner on their webpage from
"We are on track for IDE Submission to use RadioGel® in human clinical trials."
to
"We have submitted our IDE to use RadioGel® in human clinical trials."
Majority of investors don’t even have or bother with a iHub.
Ooh, I realized after the fact that was a joke and you are making fun of teachers and or students? That makes me sad. We need teachers and we need students. FYI, I still take classes and when I retire I hope to do some teaching. Education is nothing to mock.
My default is that I mispelled a word, so I just believed you. Please feel free to insult me me but figure out how to do it without making any teachers on this board feel unappreciated.
When we get the IDE, Korenko needs to start having quarterly conference calls. Some OTC CEOs do this, in fact I am pretty sure Katzoff had them in the early days. If they weren't regular quarterly CCs I believe he did have a meeting or two that we could join on line and listen to. Korenko doesn't have to answer questions on the fly but taking some ahead of time and answering our questions would be a good way to developer investor confidence.
I was on my phone. Its not a large phone screen, I can't type for crap on it plus I miss when it auto-corrects to something bizarre because it decides what I really meant. I don't care if everyone thinks I'm dumb (I am super horrible at spelling) or ignores me. I'm going to keep being me :), cheers.
You misspelled “parent/teacher” conferences ….
in your first sentence
Funny. Unless someone has zero doubts about everything the company does they have an agenda or are mentally ill.
I am not flipping and not sure why anyone would. The long term capital gains rate is too good to throw away.
At the vendor booths to get the free item you have to take the paper work. As I got older and realized the squeeze ball and pointers will never be used I stopped picking those up. That paper work is almost always tossed. That is why the free item has company info. Vinos knows this that is why the paid to be able to give away free tee-shirts with the company info. The tee shirts do the advertising. Free tee shirts are not typical at technical conferences I attend and don’t last long. Those booths are busy until they are gone.
Are there any vets here with experience at a vet conference?
Oh but they will be hearing soon ....big news with
Mayo clinic soon ....
The countdown is on 9 business days or less
IMO
It looks like there are no newbies at all and that's the problem. Nobody heard of this stock besides 800 people on this board :)
Longs are holding and newbies are waiting for IDE approval before jumping on board. Pretty simple.
I think we will be trading at .25 by the end of the week and in the .30's next week.
I don't do bipolar bashers well.. I just put them on ignore and be done with it LOL
He/maybe she, is a morally bankrupt individual who has been probably playing one end of the trade against the other. From what I have gathered from reading through this individuals posting history. He/she has had a exhibited pattern of this type posting behavior every since he/she first started posting here some time back. And to support his/hers position, depending on what position he/she may be holding at that moment, he/she comes on board to try to manipulate unstable traders emotions. From the desperation I can detect from his/hers recent negative posting activity. He/she may have found themselves on the wrong side of the trade currently. That would explain why he/she feels the need to chime in with post that have a negative slant without being to obvious. Appears to be a egotist convinced that some how some way his/hers post can influence which direction the PPS goes....
He has no clue or just another bashing trying to feed his control freak ego... He's going to my ignore list at #277 now... No tolerance for slim bashers.
Sorry dude but you have no clue... These are not local seminars with 20 card tables.. These are normally two to three days long. Companies don't fly in with $3k to $10k of equipment, set ups, and a couple reps for a two hour show LMAO.....
intellectually dishonest for you to infer it is merely 3 ladies handing out brochures that get tossed later, like that is the extent of it… depends on what they say, their conversations, their level of salesmanship at what IsoPet can successfully do
Exactly. :) This volume is so sad.
I have attended dozen of science/technical conferences and walked through miles of ball rooms with booths while holding my free drink and hor dourves. I understand well the dynamics of what is going on. What you say is true of well established technology that the professionals trust and for which they already have experience. In that case its about making a choice between different products based on price and some small differences in performance. But IsoPet is a one of a kind product and is having a very hard time in the market right now because it is a complete unknown to vets. If IsoPet is at the point of being able to attract new clinics by having three ladies pass out brochures that is fabulous. But I don't think we are. Perhaps a few of them will toss the brochure into their bag, but most paper work never makes it on a plane for the trip home from the conference it gets tossed before we leave the hotel. Being able to tell a veterinarian stopping at the table that there is another vet who has used the product who will be abilable table between 11 am and 1 pm would be a help in getting serious inquiries.
BTW, the vet that comes by and hangs out for 2 hours should not have to do any marketing. They would just get to sit there for 2 hours (paying off their free attendance and eating their lunch) and only talk with a vet that wanted to talk to them about using the product. They would be an added resource for information they would not be working to sell the product.
Can you elaborate please
It appears ALL SYSTEMS ARE GO. RDGL$.
I can tell you not a marketing person, I've been in marketing for over thirty years. You don't send out doctors, engineers, and so on, You send out the best marketing personnel that know their stuff, they know conventions, they know what's needs to be done, they are professional sales people that knows how to talk yo potential clients. They just don't sit there and watch people walk by. They get up and constantly walking to other booths smoothing with everyone at the convention. There is a lot more then sitting at a card table handing it brochures.
Well, I watch X (3 friggin different sites) and I don't see it there. I used to check on Linked in but they don't put much there. If they are only posting to instagram that is stupid. If they are going to use a half dozen social platforms they need to keep them all up to date....then again if its only more pictures of their stuffed animal and Dachund I don't care that I missed it.
Not we.. probably just you..
We didn't get a single peep from the team at their IsoPet booth at PacVet in San Francisco (July 11-14). I think they are sending the crew in the mini-van (not scientists) now instead of the big guys going. If true, that makes some sense given how many conferences they are choosing to attend. But it could also mean we not as successful at recruiting veterinarians at these events. Its hard not to notice when your talking to a marketing person at a conference booth. At that point you know its a waste of time to ask many questions, just get your swag, maybe grab a brochure and move on. Hopefully they are also flying in a vet from one of the hospitals providing IsoPet and has used it. To get a conference paid for, flight, and room and board to attend a conference in one's profession should be worth standing by a booth a few hours a day.
That appears to be the case.....
Whenever these are eligible for sale, they won’t be buying for .15 to sell for .18… sellers will be looking to sell for a minimum of .30
Ask moving up. Life is good.
That isn’t an opinion. That is fact
Imo Rdgl is preparing for Mayo human clinical trials for outpatient cancer treatments soon
It's an amendment to the prior filing and still hasn't been qualified so they can't sell any yet.
Yup he should have waited another couple weeks on that no doubt whatsoever
Oh well, I was hoping this Monday was going to be better than the last couple.
Come on, $RDGL, LFG!
New Form 1-A released this morning formally announcing RDGL making available 60M shares at $0.15.
Lmao
If u fools w stop giving the attention they so desire it wouldn't be soooo much fun for her
But a dozen times or more draws question marks does it not lol 😆
Followers
|
822
|
Posters
|
|
Posts (Today)
|
49
|
Posts (Total)
|
177068
|
Created
|
09/19/06
|
Type
|
Free
|
Moderators nathanial lovethatgreen den4 chereb19 Cameron12221 Truthsocial |
The company is engaging the FDA for permission to use RadioGel™ for the treatment of advanced basal and squamous cell skin cancers. The RadioGel™ Veterinary Solutions division of Vivos is focused on demonstrating the safety and therapeutic effectiveness for different animal cancers in four different university veterinary hospitals. Vivos is positioning itself so that after this demonstration phase, The Company can begin to generate revenues through the sale of RadioGel™ to private animal clinics.
The Company currently is outsourcing material aspects of manufacturing of its product in the United States and intends to enter into licensing arrangements outside of the United States for the manufacturing and distribution of RadioGel™ in other countries.
RadioGel™ also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to 6 weeks or more to deliver a full course of radiation therapy. This is an outpatient treatment much safer to the personnel treating the patient than competing brands and the patient can go home immediately with no risk to family members.
What are the advantages of RadioGel™?
Based upon its studies and analyses, or general application of experience with current brachytherapy devices and Yttrium-90, Vivos believes that its brachytherapy products are likely to offer the following benefits, among others, for patients and medical professionals:
•Maximizing Therapeutic Index: The short-range beta particles emitted by Y-90 deliver radiation energy within a tight range. This enables radiation to be selectively delivered to target tissues while minimizing radiation dose to nearby normal tissues. High therapeutic indices imply that more radiation energy may be imparted to target tissues, with less radiation reaching adjacent normal tissues.
•Half-Life: Y-90 has a half-life of just 2.7 days. Many traditional brachytherapy products use isotopes with longer half-lives such as 9.7 days for cesium-131, and sixty days for iodine-125.
•Optimized Delivery Method: Current brachytherapy devices place permanent metal seeds in the prostate by using up to 30 large needles. By contrast, Vivos’s Y-90 RadioGel™ device is designed to be administered in a minimally invasive procedure with small-gauge needles.
•No Permanent Seeds Remaining: Current brachytherapy devices place permanent metal seeds in the tumor. Vivos’s Y-90 RadioGel™ device utilizes a biodegradable, non-toxic polymer that is ultimately absorbed by the body. This eliminates the possibility of a long-term seed migration or other problems that may sometimes arise when seeds remain in the body.
•Good Safety Profile: Many traditional brachytherapy devices utilize isotopes that emit x-rays (akin to gamma radiation). X-rays or gamma radiation travels within and outside of the body and have long half-lives. Vivos’s brachytherapy products use the Yttrium-90 isotope, which is a beta-emitter. Yttrium-90 beta-emissions travel only a short distance and have a short half-life of 2.7 days.
•Potential Lower Cost: Yttrium-90 supplies are readily accessible and are relatively inexpensive. The elimination of the metal or glass enclosures used in traditional brachytherapy seeds greatly reduces manufacturing costs.
What is the market for RadioGel™?
Reliable sources estimate that annual sales of brachytherapy products exceed $2 billion, about half of which are in the United States. The size of the U.S. brachytherapy market for prostate cancer brachytherapy is somewhere between $90 million and $130 million per year. The market for liver and breast cancer combined is comparable.
What is Brachytherapy?
Brachytherapy is the use of radiation to destroy cancerous tumors by placing a radiation source inside or next to the treatment area. According to Global Industry Analysts, by 2016 the U.S. brachytherapy market will reach $2 billion. It is estimated that the U.S. market represents approximately half of the global market. Vivos believes there are significant opportunities in prostate, breast, liver, pancreatic, head and neck cancers. The 2013 U.S. estimated new cases according to the American Cancer Society are 240,000 prostate cancer, 235,000 breast cancer, and 31,000 liver cancer.
Are there other markets for RadioGel™?
March 15th, 2016, Vivos Inc. announced the formation of a new, wholly-owned subsidiary, IsoPet Solutions Corporation, to focus on the vibrant and expanding veterinary oncology market. In August 2017 the subsidiary was changed and made into a separate operating division inside the Company.
The IsoPet™ Veterinary Solutions division will focus on bringing RadioGel™ yttrium-90 brachytherapy products to veterinary oncologists to treat dogs and cats suffering from tumor cancers.
There are over 150 million pet dogs and cats, with over 1/3 of the households in the US owning at least one dog, and just under 1/3 owning at least one cat. IsoPet Solutions is establishing the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance. The division will also provide product awareness and education to veterinary oncologists. Initial treatments are to be coordinated through the Chair of the Company’s Veterinary Medicine Advisory Board, Dr. Alice Villalobos.
CEO and President Dr. Mike Korenko stated: “IsoPet Solutions allows specific resources to focus on the use of our RadioGel™ Yttrium-90 brachytherapy products in the veterinary space. We believe that RadioGel™ is positioned to build a significant presence in the cancer treatment tool-kit of veterinary oncologists.”
Dr. Alice stated: "I am quite excited at the opportunity to work with RadioGel's™ team to integrate their products into the cancer treatments of companion animals. Cancer affects 50% of dogs over age ten and one in four dogs under age ten. For many years, we have been searching for a useable and effective agent such as RadioGel™ Y-90 brachytherapy devices that can be delivered into tumors on an outpatient basis. I believe that veterinary oncologists around the globe will finally have an ideal product line for the treatment of accessible and inoperable tumors."
What are the steps for FDA clearance?
Vivos met at the FDA offices to discuss next steps, expectations and required testing to progress towards obtaining marketing clearance for the Y-90 RadioGel™ device. The FDA and Vivos management and consulting team are working closely in order to obtain all appropriate data and benchmarks the FDA requires in order to proceed with providing final clearance for marketing the device in the United States.
August 2016, Vivos announced a partnership with IsoTherapeutics Group, a third-party radiopharmaceutical R&D company, to provide commercialization support and conduct additional studies as requested by the FDA for the Y-90 RadioGel™ device. IsoTherapeutics has completed the first stage of the project, comprised of tech transfer, manufacturing and in vitro testing. The next stage, comprised of additional in vitro and in vivo testing. Upon completion of these studies, Vivos anticipates submittal (direct De Novo) for FDA clearance for full commercialization in the U.S. (see company press releases for continual updates on this evolving process).
Press Releases 2018 ( Change in Company name and trading symbol • Jan 2, 2018)
Jan 2, 2018, Advanced Medical Isotope Corporation (ADMD) Announces Corporate Name Change to Vivos Inc., and Ticker Symbol Change to RDGL
Press Releases 2017 ( Change in Management & Directors Dec 2016)
Dec 20, 2016, AMIC's Board of Directors Appoints Dr. Michael Korneko CEO and Dr. Carlton Cadwell Chairman of AMIC
Jan 11, 2017, AMIC's New CEO Issues Letter to Shareholders
Feb 14, 2017, AMIC's CEO Releases Shareholder Letter Outlining New Streamlined Path to FDA Submission
Feb 28, 2017, AMIC's New CEO Releases Shareholder Letter Announcing and Discussing their Cancer Indication Selection to pursue FDA Approval
Mar 7, 2017, AMIC's New CEO Releases Shareholder Letter Detailing Launch of Veterinary Oncology Division with Radiogel
Mar 23, 2017, Update on Feline Cancer Treatment and Improvement to Financial Structure
Jul 6, 2017, AMI Requests Pre-Submission Meeting with FDA
Jul 11, 2017, ADMD Makes Significant Improvement to its RadioGel™ Brachytherapy Product
Jul 27, 2017, ADMD to Host Shareholder Update Webcast with Live Q&A
Aug 2, 2017, Advanced Medical Isotope Corp. Announces Results of Shareholder Meeting, Welcomes Two New Members of the Board of Directors
Sep 14, 2017, Advanced Medical Isotope Corporation has its first discussions with private animal consortiums to utilize RadioGel™
Independent Analyst Research and Price Target
Presentation(s) from CEO & President, Dr. Mike Korenko.
2017 - LINK HERE
STOCK SYMBOL: OTC: RDGL
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |